SECTION // 08 — COLOPHON
About This Field Terminal
Clinic Wolverine is an independent editorial digest of the published research on the BPC-157 TB-500 blend. It is a reading instrument, not a medical service.
What this site is
Clinic Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a field terminal — a console that logs each peptide channel against its own studies and flags every claim about the combination as having no controlled data behind it. That format is a deliberate editorial choice. The BPC-157 TB-500 literature has a conspicuous shape: strong single-compound preclinical evidence for each peptide, and a combination claim with no study behind it. A console that renders findings as readouts, and renders the missing combination data as a gauge pinned to NO SIGNAL, makes that shape impossible to skim past.
What 'clinic' means here
The word "clinic" in this site's name is editorial framing, not a claim about services. It marks the position this publisher occupies relative to the literature — a place where the research is read closely and logged precisely — not a building where anyone is treated.
We do not offer treatment, consultation, prescription, or any clinical service. We claim no physical address, no phone line, and no clinical staff. There are no "our doctors," no "our pharmacists," and no clinical team behind this page; there is an editorial process that reads published studies and FDA sources and summarizes them with citations. When a page here describes a dose, it describes the dose administered to a specific species in a specific study — never a recommendation for any person.
How the record is kept
Every quantitative claim on this site is tied to a numbered source in the full reference list. The mechanism and efficacy findings come from the peer-reviewed literature; the evidence-quality framing comes from recent systematic and narrative reviews [6][7][8]; the regulatory facts on Wolverine legal status and FDA 503A category cite FDA pages directly.
Where the evidence is strong, this site says so plainly — BPC-157's transected-Achilles tendon repair [1] and VEGFR2-Akt-eNOS angiogenesis [2], and Thymosin Beta-4's 1:1 actin sequestration [3] are real, reproducible preclinical findings. Where the evidence is absent — no controlled combination study, no validated blend dose, no human combination safety data — this site says that too, and does not let the mechanistic rationale stand in for a result it has not produced [6].